RxDoctor Payments Data

Lorenzo Omandac, APRN

Family · Las Vegas, NVNPI 1487178927

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,528 of the $7,566 with a category attached, or 86.3%. 25 manufacturers reported payments, led by Boston Scientific at 46.5% of the total. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,566in general payments, 2019–2025

Across 147 payments — averaging $51.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Spinal Simplicity, LLC$1K
  • Medtronic$527
  • Forte Bio-pharma LLC$431
  • Biotronik NRO, Inc.$411
  • Saluda Medical Americas, Inc.$382
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,03814%
  • Food & beverage$6,52886%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,566 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$31,156
Medicare patients
225
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen461$92,604
BelbucaBuprenorphine Hcl20$14,953
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen382$8,096
Lidocaine75$5,599
Diclofenac Sodium61$5,314
Gabapentin301$3,058
Pregabalin132$2,972
Oxycodone Hcl161$2,929
Tizanidine Hcl140$1,984
Tramadol Hcl195$1,389
Celecoxib29$1,278
Ibuprofen137$1,070
Methocarbamol123$845
Morphine Sulfate ErMorphine Sulfate52$845
Duloxetine Hcl44$767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$30$14,95320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →